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Abstract
Introduction: This study aimed to compare primary percutaneous coronary intervention 
(PPCI) versus reteplase in terms of clinical and para-clinical outcomes; as well as cost-
effectiveness in patients with ST-segment-elevation myocardial infarction (STEMI).
Primary percutaneous coronary intervention is the method of choice in all patients 
especially those at higher risks. But an on-site professional team in a 24/7 facilitated system 
is a difficult goal to achieve in many areas and countries, therefore the cost-effectiveness of 
these two treatment strategies (PPCI and reteplase) needs to be discussed.
Methods: This prospective cohort study included 220 patients presented with STEMI 
who were admitted to a university hospital between January 2014 to July 2016. Patients 
were divided into two groups of 120, either receiving reteplase or PPCI. Clinical outcomes 
were considered duration of hospital stay and MACE (Major Advanced Cardiovascular 
Events) including death, cerebrovascular accident, need for repeat revascularization, and 
major bleeding. LVEF (Left ventricular ejection fraction) was considered as a para-clinical 
outcome. The outcomes and total hospital cost were compared between two treatment 
groups.
Results: Demographic characteristics between two groups of PPCI or reteplase didn’t 
show any significant differences. But in para-clinical outcomes, patients in PPCI group 
showed higher LVEF, compared with reteplase group (45.9 ± 11.5% versus 42.0 ± 11.8%; 
P = 0.02). Complication rates were similar in both groups but repeat revascularization or 
coronary artery bypass surgery was more prevalent in those who received thrombolytic 
therapy (P < 0.05). Length of hospital stay in both groups was similar in two groups but 
total cost was higher in patients who have received PPCI. (147769406.9 ± 103929358.9 
Tomans vs. 117116656.9 ± 67356122.6 Tomans; respectively, P = 0.01).
Conclusions: In STEMI patients who present during off-hours, thrombolytic therapy 
seems to represent a safe alternative to PPCI. Higher costs for patients with PPCI may be 
decreased with shorter duration of hospital stays according to guidelines.
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For prioritize and setting policies of health systems, the 
amount of available resources and their allotment way are 
among the main limiting factors. Given the high prevalence 
of heart disease, the impact of these two methods (reteplase 
and percutaneous coronary intervention) which are the main 
duties of director’s treatment in patients with ST-segment-el-
Alimohammadzadeh , et al
66
International Journal of Cardiovascular Practice 
evation myocardial infarction (STEMI), were studied in 
Imam Hussein Hospital of Tehran. Nowadays, coronary ar-
tery disease is the first cause of death in most societies. Al-
though the mortality from acute myocardial infarction has 
fallen about 30% over the past decade, approximately each 
year a million people are suffering from acute myocardial in-
farction in the United States of America. 1.2 million of the 
patients leads to death [1]. In our country cardiovascular 
disease is the top cause of mortality (46% in 2001) [2]. De-
spite the great advances which have been happened in con-
trolling and treatment of coronary artery diseases(CAD) in 
recent decades, it is predicted that by 2025, mortality from 
cardiovascular disease surpass from other causes of mortality 
(cancer, trauma, etc.) and CAD will be the foremost causes of 
mortality. Percutaneous coronary intervention is a non-sur-
gical method for treating narrowed blood vessels in coronary 
disease. Despite better clinical outcomes seen in the case of 
primary percutaneous coronary intervention (PPCI), in the 
majority of patients who do not have access to PPCI, throm-
bolytic therapy is offered as the selective treatment for reper-
fusion [3].
METHODS
This prospective observational study was conducted to deter-
mine short term cost–effectiveness of PPCI versus reteplase 
therapy in patients with STEMI. The study population in-
cluded patients with the first episode of STEMI that became 
candidates for taking thrombolytic or PPCI treatment. In this 
study, the Acute STEMI patients who were older than eigh-
teen years, involved in research out of all of the patients that 
admitted to the emergency room of Imam Hussein Hospital 
in Tehran. Acute STEMI indicator was the presence of typi-
cal angina for more than 30 minutes and less than 12 hours 
joint with STEMI electrocardiographic criteria based on 
the ACC / AHA guidelines. Patients were divided into two 
groups, one group received reteplase treatment and the sec-
ond one underwent PPCI. These groups were compared in 
terms of the following indicators:
1) Demographic characteristics.
2) Clinical criteria for hospital stay.
3) Laboratory parameters, ECG, echocardiography and an-
giography.
4) Consequences of treatment, such as mortality, the occur-
rence of re-myocardial ischemia and the need for revascu-
larization, ischemic or hemorrhagic cerebrovascular events, 
important hemorrhagic complications or need for blood 
transfusions and the need for emergency dialysis.
5) The total cost of the treatment from the time of admission 
to discharge, including medical direct costs (consumable 
equipment, personnel costs) and tariffs paid by patients, and 
hospital stay.
Information was entered to the questionnaires by the inves-
tigators and collaborator resident then was studied by sta-
tistical analysis. To use information of patients, written per-
mission was obtained from patients or their legal attendants, 
and Medical Sciences Ethics Committee of Shahid Beheshti 
University approved the project. Data were gathered by using 
both direct interviews with patients and reviewing archived 
files.
RESULTS
In this study, 220 patients with acute myocardial infarction 
were studied between the years from 2015 to 2016. Inclu-
sion criteria were the chest pain which consistent with acute 
myocardial infarction in the past twelve hours alongside 
ECG changes compatible with myocardial infarction based 
on ACC / AHA guidelines. Exclusion criteria were previous 
history of heart attack, coronary angioplasty or open heart 
surgery. The first group included 110 patients with acute 
myocardial infarction who underwent PPCI and the second 
group included 110 patients who were received reteplase. 
The average age for the first group was 61.2 ± 11.2 and for the 
second group which received reteplase was 58.6 ± 12.2 (P > 
0.05). The number of people over 75 years was equal in both 
groups and formed ten percent of the population. Gender 
distribution in the two groups of PPCI and reteplase has not 
statistically significant difference. The baseline characteristics 
of the patients are provided in Table 1.
Ischemic time in two groups of reteplase and PPCI was 6.0 
± 10.5 and 3.8 ± 5.5, respectively (P = 0.08). There weren’t 
any significant differences between two groups for clinical 
indicators of patients, laboratory tests and involved vessels at 
the time of presentation. However maximum troponin level 
was higher in the PPCI group (P = 0.03). The left ventricular 
ejection fraction (LVEF) assessed with echocardiography at 
admission time was 45.9 ± 11.5 and 11.8 ± 42.0 in patients 
who underwent PPCI and received reteplase, respectively 
(Table 2, 3).
Table 1: Demographic Indicators of Patients who Underwent PPCI or Received Reteplase
PPCI (n = 110) Reteplase (n = 110) P value
Age 61.2 ± 11.2 58.6 ± 12.2 0.105
Age over 75 years 11(10%) 11(10%) 1.000
Sex (man) 81(73.6%) 82(74.5%) 0.878
Diabetes 27(24.5%) 32(29.1%) 0.447
hypertension 47(42.7%) 42(38.2%) 0.492
Smoker 36(32.7%) 44(40%) 0.262
Family history of coronary 13(11.8%) 14(12.7%) 0.837
History of coronary disease 8(7.3%) 10(9.1%) 0.623
History of stroke 3(2.7%) 1(0.9%) 0.313
Data in table are presented as No. (%) or Mean ± SD
Abbreviations: PPCI, primary percutaneous coronary intervention
Alimohammadzadeh , et al
67
International Journal of Cardiovascular Practice 
Table 2: The baseline clinical indicators of patients who underwent PPCI or received Reteplase
PPCI (n = 110) Reteplase (n = 110) P value
Ischemic time (min) 6.0 ± 10.5 3.8 ± 5.5 0.076
Systolic blood pressure (mmHg) 126.0 ± 31.3 130.6 ± 30.6 0.253
Heart beats (per minutes) 81.0±15.8 78.6±16.5 0.281
Blood oxygen saturation 94.4±4.2 93.8±6.9 0.577
Pulmonary edema 4(3.6%) 3(2.7%) 0.701
Cardiogenic shock 10(9.1%) 8(7.3%) 0.623
Data in table are presented as No. (%) or Mean ± SD
Abbreviations: PPCI, primary percutaneous coronary intervention
Table 3: Laboratory and Angiography Indicators of Patients who Underwent PPCI or Received Reteplase
PPCI (n = 110) Reteplase (n = 110) P value
Hemoglobin (mg / dL) 13.3 ± 1.7 13.4 ± 1.7 0.627
White blood cell 10129.2 ± 9760.8 9908.5 ± 3518.6 0.826
Platelets 225343.8 ± 64702.4 247611.1 ± 73214.0 0.023
Creatinine (mg / dL) 1.1 ± 0.5 1.1 ± 0.3 0.343
Fasting glucose (mg / dL) 160.8 ± 94.4 160.6 ± 88.9 0.986
HbA1c 6.7 ± 1.5 7.8 ± 1.6 0.042
Cholesterol (mg / dL) 165.0 ± 33.5 173.9 ± 43.7 0.140
Triglycerides (mg / dL) 116.7 ± 50.0 154.2 ± 99.3 0.007
LDL (mg / dL) 98.4 ± 26.3 102.7 ± 29.5 0.363
HDL (mg/dL) 37.4 ± 7.7 38.7 ± 8.8 0.350
Primary CK-MB 81.2 ± 135.5 56.9 ± 98.3 0.147
Maximum CK-MB 184.2 ± 160.7 279.7 ± 440.1 0.108
Primary Troponin 3.6 ± 7.5 1.8 ± 6.5 0.066
Maximum Troponin 9.4 ± 9.3 14.5 ± 11.4 0.033
LVEF (%) 45.9 ± 11.5 42.0  ±11.8 0.020





Data in table are presented as No. (%) or Mean ± SD
Abbreviations: PPCI, primary percutaneous coronary intervention; LDL, Low-Density Lipoprotein; HDL, High-Density Lipoprotein; CK-
MB, Creatinine Kinase-MB; LVEF = Left Ventricular Ejection Fraction; LAD = Left Anterior Descending Artery; LCX = Left Circumflex 
Artery; RCA = Right Coronary Artery.
Table 4: Complications during Hospitalization of Patients who Underwent PPCI or Received Reteplase
PPCI (n = 110) Reteplase (n = 110) P value
Post treatment cardiac surgery 5(4.5%) 26(23.6%) 0.000
Providing balloon pump 5(4.5%) 3(2.7%) 0.471
Death 8(7.3%) 8(7.3%) 1.000
Gastrointestinal bleeding 0(0%) 2(1.8%) 0.155
Ischemic stroke 3(2.7%) 5(4.5%) 0.471
Hemorrhagic stroke 0(0%) 1(0.9%) 0.316
Post treatment ischemia 0(0%) 6(5.5%) 0.013
Reinfarction 0(0%) 2(1.8%) 0.155
Data in table are presented as No. (%).
Abbreviations: PPCI, primary percutaneous coronary intervention
Alimohammadzadeh , et al
68
International Journal of Cardiovascular Practice 
Table 5: Price Indicators of Patients who Underwent PPCI Or received Reteplase
PPCI (n = 110) Reteplase (n = 110) P value
The number of hospitaliza-
tion days
8.4 ± 7.1 9.5±5.0 0.183
Lack of insurance 0(0%) 7(6.5%) 0.006
The total cost 147769409.9 ± 103929358.9 117116656.9 ± 67356122.6 0.011
Labor costs 15215405.2 ± 39341931.4 13169090.8 ± 12103401.5 0.608
Hoteling cost 22786500 ± 35164424.9 22329299.1 ± 18169809.4 0.908
Basic insurance 123073453.0 ± 93184332.2 91685226.5 ± 58729318.6 0.004
Subsidy 10539829.7 ± 11708477.0 14431664.5 ± 9518778.3 0.009
Patient share 11716821.4 ± 21177154.6 9751561.4 ± 13471528.1 0.420
Data in table are presented as No. (%) or Mean ± SD
Abbreviations: PPCI, primary percutaneous coronary intervention
4.5% and 23.6% of the groups that underwent PPCI and 
received reteplase respectively had open heart surgery 
during hospital stay (P = 0.001). Generally, the probably of 
re-ischemic heart disease at hospital stay in reteplase group 
was higher than PPCI but myocardial infarction was not 
(P < 0.05). Other complications during hospitalization in-
cluding death, ischemic or hemorrhagic stroke, important 
bleeding such as gastrointestinal bleeding or the need for 
blood transfusions were similar between the two groups 
(P > 0.05). Complications during hospitalization for each 
group were shown in Table 4.
The mean duration of hospitalization for the patients who 
received PPCI was 8.4 ± 7.1 and 9.5 ± 5.0 for the group 
receiving reteplase, which there was not statistically sig-
nificant difference (P > 0.05). The total cost between the 
two groups showed statistically significant difference (P < 
0.05); however, hoteling cost and manpower for PPCI and 
reteplase group were not statistically significant (P > 0.05) 
(Table 5).
DISCUSSION
In patients with acute myocardial infarction who admitted 
to the hospital at the optimal time, superiority of PPCI is 
known compare to thrombolytic therapy [4]. However, all 
over the world providing environments for angiography for 
twenty-four hours a day and seven days a week is not possi-
ble. In many populated areas of the world, acute myocardial 
infarction is the first cause of death; thus high prevalence 
increases cost importance. In this study, patients’ average 
age and sex were close to some other studies [5]. Both 
groups were similar in terms of demographic indicators; 
Differences of clinical indicators or laboratory finding were 
not statistically significant. It is high lighting the findings 
worth. The high number of patients in each group had no 
similar in other national studies and provide comparison of 
findings to similar great studies [6, 7]. The most common 
vessel responsible for the infarction in both groups was left 
anterior descending artery and maximum number of in-
volved vessels was one or two which absolutely was consis-
tent with existing meta-analysis. The two treatments have 
not significant differences in terms of complications. There 
are studies that have reported complications of PPCI are 
less than thrombolytic, but the number of patients in these 
studies was higher, and the mean age of the patients in ther-
apy groups for these research is variable [8]. The mortality 
in both groups was 7.3% and entirely was close to credible 
other studies [9].
There are many studies that indicated the high value of LVEF 
for the prognosis of patients. In this study, LVEF in PPCI 
group patients at the time of hospitalization was better than 
reteplase group [9]. Hospital stay duration was similar for 
both groups, but according to other similar studies, hospi-
tal stay was longer in PPCI group in our study which is the 
positive important point that can demonstrate the need for 
a clinical review [10, 11]. The same hospital stay for both 
groups had been led to same Hoteling and Labor costs for 
reteplase and PPCI groups. However, ultimately higher con-
sumable costs in PPCI increased significantly the total cost of 
PPCI rather than reteplase group. High cost of initial hospi-
talization for patients with acute myocardial infarction who 
received primary PCI has been shown in some similar stud-
ies, and the consumable costs and the number of need for 
re-hospitalizations differences should be proved in the longer 
studies [12-15]. This article only study the short term cost of 
PPCI and reteplase therapy in patients with STEMI in Iran, 
so, the results should not extend to the long term benefits of 
PPCI versus thrombolytic therapy.
Calculation of the cost and effectiveness of the two methods 
can be a key point for decision-making and policy, contrib-
uting to implement the most appropriate treatment strategy; 
therefore they can be used for strategic planning of the Min-
istry of Health in the long term.
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